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About 70 genetic studies have already addressed the need of biomarkers to predict the response 
of patients with rheumatoid arthritis (RA) to methotrexate (MTX) treatment. However, no genetic 
biomarker has yet been sufficiently validated. Here, we aimed to replicate a selection of 25 SNPs in 
the largest collection of patients up to date, which consisted of 915 patients treated with MTX. The 
change in disease activity (measured as ΔDAS28) from baseline was considered the primary outcome. 
In addition, response according to widely used criteria (EULAR) was taken as secondary outcome. 
We considered consistency between outcomes, P values accounting for the number of SNPs, and 
independence from potential confounders for interpretation of the results. Only the rs1801394 SNP in 
MTRR fulfilled the high association standards. Its minor allele was associated with less improvement 
than the major allele according to ΔDAS28 (p = 0.0016), and EULAR response (p = 0.004), with 
independence of sex, age, baseline DAS28, smoking, seropositivity, concomitant corticosteroid use or 
previous treatments. In addition, previous evidence suggests the association of this SNP with response 
to MTX in another autoimmune disease, juvenile idiopathic arthritis, and with high intracellular folate 
levels, which could contribute to poor response.
Methotrexate (MTX) is the most widely prescribed disease-modifying anti-rheumatic drug (DMARD), and 
MTX monotherapy is the first treatment recommended for most new patients with rheumatoid arthritis (RA)1,2. 
However, a significant decrease in disease activity is not observed at six months of follow-up in a sizable frac-
tion of patients. This variable response calls for biomarkers to predict patients with low chances of benefiting 
from MTX monotherapy. The biomarkers have been searched specially in the area of pharmacogenetics3–5. About 
1Experimental and Observational Rheumatology and Rheumatology Unit, Instituto de Investigación Sanitaria - 
Hospital Clínico Universitario de Santiago, Travesia Choupana sn, 15706, Santiago de Compostela, Spain. 2CESPU, 
Institute of Research & Advanced Training in Health Sciences & Technologies, Department of Pharmaceutical 
Sciences, Rua Central de Gandra, 1317, 4585-116, Gandra, PRD, Portugal. 3Faculty of Medicine of University of 
Porto, Alameda Prof. Hernâni Monteiro, 4200-319, Porto, Portugal. 4Rheumatology Department of São João 
Hospital Center, Porto, Portugal. 5Department of Physiology, Pomeranian Medical University Szczecin, Rybacka 
1, 70-204, Szczecin, Poland. 6Department of Biochemistry and Molecular Biology, National Institute of Geriatrics, 
Rheumatology and Rehabilitation, Spartańska 1, 02-637, Warsaw, Poland. 7Department of Rheumatology, Wroclaw 
Medical University, Ludwika Pasteura 1, 50-367, Wroclaw, Poland. 8Department of Genetics, Wroclaw Medical 
University, Ludwika Pasteura 1, 50-367, Wroclaw, Poland. 9Pharmacogenetics Laboratory, Institute of Biochemistry, 
Faculty of Medicine, University of Ljubljana, Vrazov Trg 2, 1000, Ljubljana, Slovenia. 10Rheumatology Department, 
Instituto de Investigacion del Hospital de La Princesa (IIS-IP), Diego de León 62, 28006, Madrid, Spain. 11Department 
of Rheumatology, Hospital Universitario de Bellvitge-IDIBELL, Carrer de la Feixa Llarga, s/n, 08907, Barcelona, Spain. 
12Rheumatology Unit, Hospital Universitario Virgen de las Nieves, Av. de las Fuerzas Armadas, 2, 18014, Granada, 
Spain. Correspondence and requests for materials should be addressed to A.G. (email: agmartinezp@ser.es)
Received: 9 November 2017
Accepted: 24 April 2018
Published: xx xx xxxx
OPEN
www.nature.com/scientificreports/
2SCIENTIFIC REPORTS |  (2018) 8:7342  | DOI:10.1038/s41598-018-25634-y
70 studies have explored polymorphisms in candidate genes including the primary target of MTX, the enzyme 
dihydrofolate reductase (DHFR), which converts dihydrofolate to tetrahydrofolate. Tetrahydrofolate is essential 
for purine synthesis, and in the biologically active form, 5-methyl-tetrahydrofolate, is an important cofactor in 
one-carbon metabolism. Candidate genes are involved in the transport of MTX, generation of its active metabo-
lites, MTX polyglutamates, or in folate one-carbon metabolism, purine synthesis, or in the biosynthetic pathway 
for adenosine whose accumulation could be the main anti-inflammatory effect of MTX treatment3,4. However, no 
reproducible association has emerged yet from these candidate gene studies. This panorama has been completed 
recently, thanks to the first GWAS, which was performed in RA patients from the North of India6. The authors 
highlighted 7 SNPs with suggestive evidence of association, none of them located in candidate loci, and several 
SNPs in candidate genes, which were only apparent after specifically looking for them.
Here, we aimed to replicate 25 of the most promising genetic biomarkers previously associated with MTX 
response. Fourteen were selected from candidate gene studies3,4,7–21, and 11 were selected from the recent GWAS6. 
They were analyzed in the largest collection of patients with RA studied to date and with a focus in reproducibil-
ity of the results22. A SNP in MTRR, rs1801394, showed robust association. None of the other SNPs reached our 
demanding standards.
Materials and Methods
Patients. The study population consisted of 956 patients with RA according to the 1987 American College 
of Rheumatology criteria23. They were of European Caucasian origin, and more specifically of Spanish (269), 
Slovenian (103), Portuguese (230) and Polish (354) origin. The patients were recruited with written informed 
consent. The study was approved by the Autonomous Research Ethics Committee of Galicia (Ref. 2014/387). All 
protocols and methods were conducted according with the relevant guidelines (Declaration of Helsinki and the 
Belmont Report) and regulations (Spanish Law 14/2007 of Biomedical Research). All patients have received MTX 
monotherapy for 6 months. Evaluations included Disease Activity Score 28 (DAS28) at the start of treatment and 
at 6 months. DAS28 is a composite index of RA activity including the number of tender joints and swollen joints 
(28 joints maximum), erythrocyte sedimentation rate, and global patient health status assessment24. DAS28, at 
the start of the treatment and at 6 months, sex and age were used for all analyses. This information was incomplete 
in 41 patients that were excluded. Main clinical characteristics of the remaining 915 patients are summarized in 
Table 1.
SNP selection and testing. We selected 25 SNP for study (Supplementary Table S1 for full details and 
references): 14 SNPs from candidate gene studies, and 11 SNPS from a GWAS. Genotypes were determined 
by PCR amplification followed by single-base extension with the SNaPshot Multiplex Kit (Applied Biosystems, 
Foster City, California). The corresponding primers, probes and detailed protocols are available from the authors. 
Quality control of the results included duplicate assays of 10% of the samples, genotype call rate ≥95%, concord-
ance with the Hardy–Weinberg equilibrium (p > 0.01) and with the SNP frequencies in the HapMap European 
collection (Utah residents with Northern and Western European ancestry and Iberian populations in Spain taken 
from http://browser.1000genomes.org/index.html). One SNP (rs1051266) was excluded due to low call rate.
Characteristic Value PΔDAS28a PNRb
Women, N (%) 738 (80.6) 0.002 ns
Age at treatment, mean ± SD 52.7 ± 13.7 <10−5 0.0003
RF positive, N (%) 555 (60.6) ns ns
Anti-CCP positivec, N (%) 501 (54.7) 0.001 0.03
Seropositivity (RF or antiCCP) 682 (74.5) 0.002 ns
Erosive arthritis, N (%) 479 (52.3) <10−6 <10−5
Smoking habitc, N (%) 195 (21.3) ns 0.003
Previous DMARD, N (%) 185 (20.2) <10−6 <10−5
MTX maximum dosec, mean ± SD 18.7 ± 4.6 ns ns
Concomitant treatment
  Corticosteroids, N (%) 660 (72.1) 0.01 0.01
  NSAIDsc, N (%) 490 (53.5) 0.0004 <10−5
Baseline DAS28, mean ± SD 5.3 ± 1.2 <10−6 <10−4
DAS28 at 6 months, mean ± SD 4.0 ± 1.5
EULAR response at 6 months, N (%)
  Good responder 250 (27.3)
  Moderate responder 354 (38.7)
  Non-responder 311 (34.0)
Table 1. Characteristics of the 915 patients with RA and their association with response to MTX. aResponse 
to MTX assessed as ΔDAS28 and analyzed with linear regression. bResponse to MTX assessed as EULAR non-
response (NR) and analyzed with logistic regression. cData from <85% of the patients were available.
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Statistical analyses. Response to MTX was evaluated as change in DAS28 at 6 months of follow-up 
(ΔDAS28 = DAS28baseline − DAS28follow-up) as the primary outcome. In addition, non-responder classifica-
tion according to the European League Against Rheumatism (EULAR) criteria was also assessed25. The EULAR 
criteria divide patients into three classes based on change in DAS28 from baseline (ΔDAS28) and DAS28 at the 
time of evaluation: good responders are those with ΔDAS28 ≥ 1.2 and DAS28 ≤ 3.2; non-responders (NR) are 
all patients with ΔDAS28 ≤ 0.6 and those with ΔDAS28 > 0.6 but ≤1.2 and with DAS28 > 5.1; all the remaining 
patients are moderate responders. Here, good and moderate responders were grouped as responders (n = 604) to 
confront with the NR (n = 311). Linear and logistic regression models for ΔDAS28 and EULAR NR were fitted, 
respectively. Genotypes were considered in accordance with an additive genetic model of minor allele counts (0, 
1 or 2). Therefore, positive regression coefficients indicate a better response associated with minor allele additive 
effects. Effect of each SNP was adjusted for sex, age, DAS28 at baseline, treatment with a previous DMARD and 
concomitant treatment with corticosteroids. In a second analysis, additional putative confounders were included: 
seropositivity and smoking status. Data from the four populations were combined by individual participant data 
metaanalysis applying two-stage methods. They involved estimation of the association parameters for each pop-
ulation as the first stage and the combination of the results of the four populations in the second stage. A main 
effects linear regression model for each population was applied to ΔDAS28. The EULAR outcome, in turn, was 
assessed with separate logistic regression for each population. The combination was done as fixed effects, weight-
ing the effect corresponding to each population with the inverse variance method, and as random effects, accord-
ing to DerSimonian and Laird. The fixed effects results were preferred except when heterogeneity was moderate 
(I2 > 50), in which case the random effects metaanalysis was selected. Heterogeneity of effect sizes between popu-
lations was assessed with Cochran Q test and the inconsistency parameter I2. Results were interpreted considering 
the number of tests following the Bonferroni approach, concordance of results with the two treatment outcomes, 
independence from confounding variables, and previous evidence of association with response to MTX. Statistica 
7.0 (Statsoft, Tulsa, OK, USA) was used for analyses. Post-hoc power analysis was used to assess the study capacity 
to replicate previous findings. The effect size to replicate was taken from previous studies, considering the EULAR 
response because this is the most frequently reported outcome in previous studies. The power analysis was con-
ducted using the GPower NT software for the most extreme reported OR26.
Data availability. The datasets generated during the current study are available from the corresponding 
author on reasonable request
Results
The 915 RA patients were predominantly female (81%) and DMARD-naïve (80%) with a mean age of 53 years at 
the start of MTX monotherapy (Table 1). According to baseline DAS28, many patients presented a high disease 
activity (DAS28 > 5.1) and most of them received concomitant treatment with corticosteroids or NSAIDs (72.1% 
and 53.5%, respectively). After 6 months on MTX, only 27.3% of the patients showed a good response according 
to EULAR criteria, 38.7% showed a moderate response and 34.0% were NR. Several of the clinical and demo-
graphic variables were significantly associated with ΔDAS28 or with NR (Table 1). Specifically, men, seronega-
tive patients, patients lacking erosions, not DMARD-experienced or not receiving concomitant corticosteroids 
showed larger decrease in DAS28 than the corresponding alternative patient subgroups. Associations with NR 
were similar (Table 1).
After genotyping and quality control, one of the 25 SNPs was discarded. Fixed effect metaanalysis of the nested 
models on the remaining 24 SNPs showed nominal association with ΔDAS28 (Table 2) of two SNPs from candi-
date genes (rs2295553 and rs1801394). Only rs1801394 in MTRR showed association withstanding Bonferroni 
correction (P = 0.0016). Its minor allele (A) was associated with a lower decrease in DAS28 after MTX treatment 
than the major allele, specifically, 0.14 less DAS28 units per each A allele according with the additive model. The 
magnitude of change showed a low level of heterogeneity between the four populations (I2 = 24%) that was not 
significant according with the Q test (P = 0.3) and did not reflect any widely divergent result (Fig. 1).
The previous results were obtained with adjustment by five clinical variables (sex, age, baseline DAS28, pre-
vious DMARD treatment and concomitant corticosteroids), which were available from most of the 915 patients. 
Multivariate analysis adjusting for two other variables associated with response to MTX (smoking and seropositiv-
ity) was only possible in 643 patients (Supplementary Table S2). Therefore, the results were compared at the level of 
effect sizes, which are independent of the number of samples, not at the level of P values, which are very sensitive to 
the number of patients. The effect size of rs1801394 was almost unaltered (from β = −0.14 to −0.13; P = 0.009) after 
the complete adjusted analysis. No other SNP than rs1801394 showed association (P < 0.05) in this set of analyses.
Consideration of the secondary outcome of response to MTX, NR according to EULAR criteria, showed a 
consistent association of rs1801394 (Table 3). The A allele showed OR = 1.39 for NR (95% CI 1.11–1.75) without 
detectable heterogeneity between the populations (I2 = 0). There were three other SNPs showing nominal associ-
ation (rs4673990, rs2372536 and rs2650972) with little heterogeneity between the populations. As for the primary 
outcome, inclusion of more variables of adjustment did not modify the effect size of rs1801394 (from OR = 1.39 
to 1.37) reinforcing the evidence of its independent association with MTX response (Supplementary Table S2). 
Two of the other SNPs showing association with NR were reinforced in the fully adjusted analysis (rs4673990 and 
rs2372536), but at the expense of increased heterogeneity between the populations.
Discussion
Here, we have identified a SNP, rs1801394, in MTRR associated with response to MTX with all the characteristics 
we had specified in advance to increase reproducibility22. This focus in reproducibility differs from many previous 
studies on the same field3–5. The remaining 23 SNPs from candidate gene studies or from GWAS did not show 
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Locus SNP MA
Fixed effects Heterogeneity Random effects
β (SE) P I2 P β (SE) P
Candidate gene
   ABCB1 rs1045642 A 0.02 (0.04) 0.6 28 0.2 0.02 (0.05) 0.7
   ABCC1 rs35592 C 0.03 (0.05) 0.6 71 0.02 −0.04 (0.10) 0.7
   AMPD1 rs17602729 A −0.11 (0.07) 0.10 61 0.05 −0.17 (0.12) 0.15
   ATIC rs4673990 G 0.08 (0.04) 0.07 6 0.4 0.08 (0.05) 0.09
rs12995526 A 0.04 (0.04) 0.4 36 0.2 0.02 (0.06) 0.7
rs16853834 T 0.04 (0.06) 0.6 11 0.3 0.04 (0.07) 0.6
rs2372536 G 0.07 (0.05) 0.1 17 0.3 0.07 (0.06) 0.2
   ITPA rs2295553 C 0.09 (0.04) 0.040 0 0.6 0.09 (0.04) 0.040
rs1127354 A 0.07 (0.09) 0.4 19 0.3 0.06 (0.10) 0.5
   MTRR rs1801394 A −0.14 (0.04) 0.0016 24 0.3 −0.15 (0.05) 0.0056
   MTHFD1 rs2236225 A −0.06 (0.05) 0.2 0 0.8 −0.06 (0.05) 0.2
   SLC46A1 rs2239907 T −0.01 (0.04) 0.7 0 0.6 −0.01 (0.04) 0.7
   TYMS rs699517 T −0.03 (0.05) 0.5 57 0.07 0.00 (0.08) 1.0
GWAS hit
   ARL14/PPM1L rs7624766 G −0.03 (0.05) 0.5 0 0.5 −0.03 (0.05) 0.5
   BMP2 rs2650972 T −0.04 (0.04) 0.4 0 0.8 −0.04 (0.04) 0.4
   DHFR rs5836788 del −0.01 (0.05) 0.8 0 0.5 −0.01 (0.05) 0.8
   10p15.1 rs1901633 G 0.05 (0.05) 0.3 0 0.7 0.05 (0.05) 0.3
   14q13.1 rs4982133 A −0.06 (0.05) 0.3 0 1.0 −0.06 (0.05) 0.3
   15q26.2 rs1703794 C −0.01 (0.05) 0.8 0 0.4 −0.01 (0.05) 0.8
   20q13 rs6064463 C −0.06 (0.05) 0.2 11 0.3 −0.06 (0.05) 0.3
   MTRR rs162040 C −0.07 (0.06) 0.3 60 0.06 −0.07 (0.11) 0.5
   PTPRM rs6506569 C 0.02 (0.05) 0.6 0 0.8 0.02 (0.05) 0.6
   TYMS rs2244500 G 0.02 (0.05) 0.6 64 0.04 0.07 (0.09) 0.4
rs2847153 A 0.02 (0.06) 0.7 0 0.5 0.02 (0.06) 0.7
Table 2. Metaanalysis of the association of the 24 SNPs with response to MTX assessed as ΔDAS28 at 6 months 
in the four populations of RA patients. Summary regression coefficients (β) and their standard errors (SE) 
obtained with fixed effects and random effects metaanalysis are presented together with the inconsistency (I2) 
and P value of the Cochran Q test for heterogeneity. Multivariate linear regression in each population included 
sex, age, baseline DAS28, previous use of DMARD and concomitant treatment with corticosteroids.
Figure 1. Forest plot of the fixed effects metaanalysis for association of rs1801394 with ΔDAS28 in patients 
with RA treated with MTX. Square areas are proportional to the weight of the population according to the 
inverse variance method. Width of the diamond represents the 95% CI of the summary regression coefficient.
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association at these high standards. These results have the added value of arising from the largest collection of 
patients analyzed to date in the genetics of response to MTX.
The association of rs1801394 (also called A66G) with response to MTX fulfilled all the requirements of our 
analysis: its P value was low enough to allow for correction by the number of tests, it was consistently observed 
with the two treatment outcomes (although the NR P value was over the corrected threshold), ΔDAS28 and 
EULAR criteria, and it was independent of the other variables with influence on response to MTX, including 
differences in disease activity, treatment and sample collection. These requisites were considered necessary to 
increase reproducibility, which is critical for validation of any biomarker3–5,22.
The uncritical use of P < 0.05 for claiming association has been shown to lead to many false positive results. 
Correction by the number of tests, although not without limitations, is widely considered to be very beneficial 
in genetics of complex diseases22,27. Other characteristic that distinguishes our analysis is the adjustment for 
multiple potential confounding variables. Variables like the baseline level of disease activity or the previous use 
of DMARDs could have a different distribution in patients with different genotypes and introduce bias in the 
results as they are strongly associated with MTX response. Another distinctive characteristic of our study is anal-
ysis according to the additive genetic model with values 0, 1 and 2 for the number of minor alleles. In selecting 
the additive model we have followed the approach of the GWAS that have chosen the additive model based in its 
biological plausibility and statistical reproducibility27.
Less consensus exists in the outcome that should be used in the search of biomarkers of response to treatment 
in RA. ΔDAS28 has all the advantages of quantitative traits in comparison with dichotomous traits for statistics: 
discrimination, robustness, increased power and reproducibility28,29. These considerations motivated our use of 
ΔDAS28 as the primary outcome for analysis, which is concordant with the large studies and joint initiatives 
analyzing response to biologic DMARDs30–32. The only advantage of dichotomous outcomes is its simplicity. 
However, this simplicity is misleading because definitions of NR vary widely between studies. In effect, some 
authors have used the EULAR criteria of response, others have used DAS28-based remission, or low-disease 
activity, or the ACR 20 and ACR 50 response criteria, and even study-specific definitions of response4. As a 
Locus SNP MA
Fixed effects Heterogeneity Random effects
OR (95% CI) P I2 P OR (95% CI) P
Candidate gene
   ABCB1 rs1045642 A 0.95 (0.8–1.2) 0.6 22 0.3 0.97 (0.7–1.2) 0.8
   ABCC1 rs35592 C 1.19 (0.9–1.5) 0.2 61 0.05 1.24 (0.8–1.9) 0.3
   AMPD1 rs17602729 A 1.08 (0.8–1.5) 0.6 42 0.2 1.14 (0.7–1.8) 0.6
   ATIC rs4673990 G 0.73 (0.6–0.9) 0.009 0 0.5 0.73 (0.6–0.9) 0.009
rs12995526 A 0.85 (0.7–1.1) 0.1 52 0.10 0.86 (0.6–1.2) 0.4
rs16853834 T 0.91 (0.7–1.3) 0.6 0 0.5 0.91 (0.7–1.3) 0.6
rs2372536 G 0.72 (0.6–0.9) 0.009 8 0.4 0.72 (0.6–0.9) 0.014
   ITPA rs2295553 C 0.81 (0.6–1.02) 0.1 0 1.0 0.81 (0.6–1.02) 0.1
rs1127354 A 0.74 (0.5–1.1) 0.2 0 0.6 0.74 (0.5–1.1) 0.2
   MTRR rs1801394 A 1.39 (1.1–1.8) 0.004 0 0.6 1.39 (1.1–1.8) 0.004
   MTHFD1 rs2236225 A 1.03 (0.8–1.3) 0.8 0 0.5 1.03 (0.8–1.3) 0.8
   SLC46A1 rs2239907 T 0.96 (0.8–1.2) 0.7 0 0.8 0.96 (0.8–1.2) 0.7
   TYMS rs699517 T 1.03 (0.8–1.3) 0.8 0 0.6 1.03 (0.8–1.3) 0.8
GWAS hit
   ARL14/PPM1L rs7624766 G 1.13 (0.9–1.4) 0.3 47 0.13 1.15 (0.8–1.6) 0.4
   BMP2 rs2650972 T 1.28 (1.02–1.6) 0.035 0 0.8 1.28 (1.02–1.6) 0.035
   DHFR rs5836788 del 1.00 (0.8–1.3) 1.0 17 0.3 1.00 (0.8–1.3) 1.0
   10p15.1 rs1901633 G 0.88 (0.7–1.1) 0.3 0 0.9 0.88 (0.7–1.1) 0.3
   14q13.1 rs4982133 A 1.19 (0.9–1.6) 0.2 0 0.7 1.19 (0.9–1.6) 0.2
   15q26.2 rs1703794 C 1.12 (0.9–1.5) 0.4 5 0.4 1.12 (0.8–1.5) 0.4
   20q13 rs6064463 C 1.17 (0.9–1.5) 0.2 0 0.5 1.17 (0.9–1.5) 0.2
   MTRR rs162040 C 1.35 (0.98–1.9) 0.1 0 1.0 1.35 (0.98–1.9) 0.1
   PTPRM rs6506569 C 0.89 (0.7–1.1) 0.3 0 0.5 0.89 (0.7–1.1) 0.3
   TYMS rs2244500 G 0.89 (0.7–1.1) 0.4 0 0.9 0.89 (0.7–1.1) 0.4
rs2847153 A 1.02 (0.8–1.4) 0.9 0 0.7 1.02 (0.8–1.4) 0.9
Table 3. Metaanalysis of the association of the 24 SNPs with response to MTX according to the EULAR 
criteria at 6 months in the four populations of RA patients. Summary odds ratios (OR) and their confidence 
intervals (95% CI) obtained with fixed effects and random effects metaanalysis are presented together with 
the inconsistency (I2) and p value of the Cochran Q test for heterogeneity. Multivariate logistic regression in 
each population included sex, age, baseline DAS28, previous use of DMARD and concomitant treatment with 
corticosteroids.
www.nature.com/scientificreports/
6SCIENTIFIC REPORTS |  (2018) 8:7342  | DOI:10.1038/s41598-018-25634-y
consequence, it is suspected that heterogeneity in these definitions could contribute to lack of reproducibility. In 
any case, we decided to include the EULAR criteria as a secondary outcome for completeness.
All the discussed characteristics were intended to increase the reproducibility of our results. However, the 
association of response to MTX with rs1801394 in MTRR is not yet certain. Additional support could be obtained 
from its credibility as a good candidate22. This SNPs causes the substitution of isoleucine for methionine at amino 
acid 22 of MTRR, 5-methyltetrahydrofolate-homocysteine methyltransferase reductase. This enzyme collabo-
rates with MTR (5-methyltetrahydrofolate-homocysteine methyltransferase) in the transfer of a methyl group 
from 5-methy tetra-hydro-folic acid to homocysteine, resulting in de novo production of L-methionine and 
tetra-hydro-folic acid (in a reaction involving vitamin B12 as cofactor). This step in the folic acid cycle precedes 
the production of the active form of L-methionine, S-adenosyl-methionine, which is the methyl donor in hun-
dreds of biologic transmethylation reactions and the donor of propylamine in polyamine synthesis. Specifically, 
the A allele, herein associated with poor response to MTX, has been related to a moderate decrease in total plasma 
levels of homocysteine, which is interpreted as increased capacity to regenerate methionine33. More pertinent 
for our study, patients with RA under MTX treatment displayed folate levels in red blood cells (RBC) that were 
higher in carriers of the rs1801394 A allele compared to the G/G genotype16. This relationship between MTRR 
and intracellular folate could be linked with the association we have observed because RA patients displaying 
a decrease in RBC folate (in the form of folate polyglutamates) concentration during MTX treatment showed 
a marked decrease of DAS28 at 6 months18. This indirect relationship seems to indicate that the A allele could 
decrease response to MTX by leading to increased intracellular folate, which is a factor already suspected due 
to the interference of folic or folinic acid supplementation with MTX treatment34–36. However, the more direct 
evidence linking rs1801394 with response to MTX comes from previous genetic studies. There have been three 
studies analyzing rs1801394 as a biomarker of response to MTX in patients with RA18,19,37, and two in patients 
with juvenile idiopathic arthritis (JIA)38,39. Two of these studies, one in RA19, and one in JIA38 have found the same 
association reported here. The negative studies were either smaller (n = 48 in18, and 119 in39) or from a different 
ethnic background (n = 322 Indians in37). As the RA study that has found association overlaps with our study19, 
we analyzed the association between rs1801394 and treatment response after excluding the overlapping collection 
of patients, finding similar effect sizes (n = 664 patients; ΔDAS28 β = −0.19, SE = 0.06, P = 0.002; NR OR = 1.33, 
95% CI = 1.03–1.7, P = 0.030) to those obtained in the total population. Therefore, we can conclude that previous 
evidence supports a functional relationship of rs1801394 with alterations in the folate pathway and provide sug-
gestive support of its association with response to treatment, although further validation is still needed.
In this study, we analyzed other 23 SNPs from previous candidate gene studies and from a GWAS 
(Supplementary Table S1). However, none showed an association below the corrected threshold or was asso-
ciated with the two outcomes at the nominal level of P < 0.05. In addition, three of the four that showed nomi-
nal association in any analysis, rs2295553, rs4673990 and rs2372536, were in the opposite direction to previous 
reports. The only concordant SNP, rs2650972, was just below the 0.05 level for the EULAR outcome (P = 0.035) 
and far over this threshold for ΔDAS28. This lack of reproducibility is common for candidate gene studies, as 
signaled by previous systematic revisions and meta-analysis3–5. The causes are many, but it is worth to highlight 
that the candidate gene approach responds to a concept of complex traits that has been demonstrated overly 
optimistic. In fact, progress in genetics has shown that many complex traits have very polygenic causality with 
many involved loci, each of them with very small contribution. Therefore, the candidate gene approach has been 
almost abandoned in favor of GWAS, which are done in much larger sample collections and with strict quality 
control and requirements to claim association27. Unfortunately, the new requirements are hard to fulfill in areas 
like the response to treatment in RA. This is exemplified by the study of response to TNF inhibitors, where only 
after multiple consortia it was possible to put together about 3000 patients30. The GWAS on response to MTX in 
comparison only included 457 patients and none of the highlighted loci reached the threshold of significance set 
for this type of studies6. Therefore, it is not surprising that we did not replicate any of the SNPs selected from that 
GWAS in our study.
Our study shows some limitations that include lack of complete information from all patients, possible con-
founding by indication common to retrospective studies without randomization, the requirement of 6 months 
on MTX and insufficient power to detect associations with small effect sizes, which are common in complex 
traits. However, statistical power of our study was sufficient to replicate previous published effect sizes. Only 
a SNP did not show power >0.8 to replicate previously findings with P < 0.05. This SNP was rs162040, which 
showed power = 0.71 for detecting association with P < 0.05. As the OR of rs162040 in our study was 1.35 with-
out heterogeneity and the OR in the previous study was 1.45 and with similar increase in NR associated with 
the minor allele6, it is possible that lack of power has been an issue in our results for this SNP. This possibility is 
interesting because rs162040 is also in the MTRR locus. The next weakest power was obtained for rs2847153 that 
showed power = 0.82 for association with P < 0.05. However, in this case the effect size in our samples was so low 
(OR = 1.02) that lack of power did not seem relevant. All the other SNPs showed power ≥0.79 for replication of 
published effects with P < 0.01. Therefore, the association of rs1801394 needs to be replicated in other context 
not only to confirm its accuracy, but also to know if it extends to other patient groups, including other ethnic 
backgrounds, and study designs.
In conclusion, our results show only a SNP, rs1801394, in MTRR with a robust association with response to 
MTX monotherapy among the 24 analyzed. This association surpassed all the requirements we have imposed 
aiming to increase reproducibility and was supported by the study sample size, the largest to date on MTX treat-
ment, and suggestive evidence about the SNP function and previous association data. However, it still needs 
confirmation. It is to be expected this finding could stimulate further collaborations and efforts to progress in the 
search of biomarkers predicting the important outcome of MTX treatment.
www.nature.com/scientificreports/
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